IL138021A0 - High affinity humanized anti-tag-72 monoclonal antibodies - Google Patents
High affinity humanized anti-tag-72 monoclonal antibodiesInfo
- Publication number
- IL138021A0 IL138021A0 IL13802198A IL13802198A IL138021A0 IL 138021 A0 IL138021 A0 IL 138021A0 IL 13802198 A IL13802198 A IL 13802198A IL 13802198 A IL13802198 A IL 13802198A IL 138021 A0 IL138021 A0 IL 138021A0
- Authority
- IL
- Israel
- Prior art keywords
- tag
- monoclonal antibodies
- high affinity
- humanized anti
- affinity humanized
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5756—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving tumour-associated glycolinkage [TAG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Food Science & Technology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US1998/003679 WO1999043816A1 (en) | 1998-02-25 | 1998-02-25 | High affinity humanized anti-tag-72 monoclonal antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL138021A0 true IL138021A0 (en) | 2001-10-31 |
Family
ID=22266462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL13802198A IL138021A0 (en) | 1998-02-25 | 1998-02-25 | High affinity humanized anti-tag-72 monoclonal antibodies |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1056860B1 (de) |
| JP (1) | JP4080692B2 (de) |
| AT (1) | ATE288960T1 (de) |
| AU (1) | AU758358B2 (de) |
| CA (1) | CA2321932A1 (de) |
| DE (1) | DE69829001T2 (de) |
| IL (1) | IL138021A0 (de) |
| NO (1) | NO20004250L (de) |
| WO (1) | WO1999043816A1 (de) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6818749B1 (en) | 1998-10-31 | 2004-11-16 | The United States Of America As Represented By The Department Of Health And Human Services | Variants of humanized anti carcinoma monoclonal antibody cc49 |
| CA2348698C (en) * | 1998-10-31 | 2012-01-03 | Syed V. S. Kashmiri | Variants of humanized anti-carcinoma monoclonal antibody cc49 |
| WO2002096948A2 (en) | 2001-01-29 | 2002-12-05 | Idec Pharmaceuticals Corporation | Engineered tetravalent antibodies and methods of use |
| EP1532162B1 (de) | 2002-06-28 | 2013-08-07 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Humanisierter anti-tag-72 cc49 zur diagnose und therapie humaner tumore |
| WO2005021594A2 (en) | 2003-08-29 | 2005-03-10 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Minimally immunogenic variants of sdr-grafted humanized antibody cc49 and their use |
| KR100620554B1 (ko) * | 2004-06-05 | 2006-09-06 | 한국생명공학연구원 | Tag-72에 대한 인간화 항체 |
| US8101728B2 (en) | 2005-04-28 | 2012-01-24 | Danisco Us Inc. | TAB molecules |
| CA2609142C (en) | 2005-05-27 | 2016-02-09 | Fondazione Centro San Raffaele Del Monte Tabor | Therapeutic gene vectors comprising mirna target sequences |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE64966B1 (en) * | 1988-10-19 | 1995-09-20 | Dow Chemical Co | A novel family of high affinity modified antibodies for cancer treatment |
-
1998
- 1998-02-25 AT AT98910057T patent/ATE288960T1/de not_active IP Right Cessation
- 1998-02-25 EP EP98910057A patent/EP1056860B1/de not_active Expired - Lifetime
- 1998-02-25 DE DE69829001T patent/DE69829001T2/de not_active Expired - Lifetime
- 1998-02-25 AU AU64393/98A patent/AU758358B2/en not_active Ceased
- 1998-02-25 WO PCT/US1998/003679 patent/WO1999043816A1/en not_active Ceased
- 1998-02-25 CA CA002321932A patent/CA2321932A1/en not_active Abandoned
- 1998-02-25 JP JP2000533556A patent/JP4080692B2/ja not_active Expired - Lifetime
- 1998-02-25 IL IL13802198A patent/IL138021A0/xx unknown
-
2000
- 2000-08-24 NO NO20004250A patent/NO20004250L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20004250L (no) | 2000-10-24 |
| EP1056860B1 (de) | 2005-02-09 |
| WO1999043816A1 (en) | 1999-09-02 |
| AU758358B2 (en) | 2003-03-20 |
| NO20004250D0 (no) | 2000-08-24 |
| JP2002504371A (ja) | 2002-02-12 |
| DE69829001T2 (de) | 2006-03-23 |
| EP1056860A1 (de) | 2000-12-06 |
| JP4080692B2 (ja) | 2008-04-23 |
| ATE288960T1 (de) | 2005-02-15 |
| CA2321932A1 (en) | 1999-09-02 |
| AU6439398A (en) | 1999-09-15 |
| DE69829001D1 (de) | 2005-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0311792A (pt) | Anticorpo de receptor anti-igf-i | |
| SG170080A1 (en) | Human monoclonal antibodies to o8e | |
| WO2005080431A3 (en) | Monoclonal antibodies that specifically bind to folate receptor alpha | |
| WO1998035693A3 (en) | Detection and modulation of the iaps and naip for the diagnosis and treatment of proliferative disease | |
| EA200800094A1 (ru) | Антитела cd19 и их использование | |
| AU2003205077A1 (en) | Imaging agents and methods of imaging naaladase of psma | |
| EP2196474A3 (de) | Therapeutische Zielmolekulen in Krebs | |
| IN2009KN02404A (de) | ||
| HUP9901562A2 (hu) | Anti-CEA monoklonális antitestek, az ezeket tartalmazó konjugátumok és ezek felhasználása antitest irányított enzimes előgyógyszer terápiában | |
| WO2004058146A3 (en) | Novel compositions and methods in cancer | |
| IL139700A0 (en) | Immunotherapeutic composition and method for the treatment of prostate cancer | |
| IL148113A0 (en) | Ovarian cancer cell and myeloma cell surface glycoproteins, antibodies thereto, and uses thereof | |
| IL176007A0 (en) | Antibodies specific to c35 and pharmaceutical compositions containing the same | |
| SG146644A1 (en) | Kid3 and kid3 antibodies that bind thereto | |
| WO2004060304A3 (en) | Novel compositions and methods in cancer | |
| WO2003064593A3 (en) | Antigen panels and methods of using the same | |
| WO2002064839A3 (en) | Methods for the diagnosis and treatment of tumors employing the hepsin gene | |
| IL138021A0 (en) | High affinity humanized anti-tag-72 monoclonal antibodies | |
| NO20004251L (no) | Humaniserte anti-CEA monoklonale antistoffer med høy affinitet | |
| WO2003080808A3 (en) | Novel compositions and methods in cancer | |
| EA200601405A1 (ru) | Гуманизированное антитело | |
| EA200600995A1 (ru) | Молекулы, ингибирующие ангиогенез, и их применение в лечении и диагностике рака | |
| WO2002057786A3 (en) | Compositions and methods for the use of fibronectin fragments in the diagnosis of cancer | |
| AU2001233917A1 (en) | Bcmp-7 as marker for diagnosis of breast cancer | |
| WO2004101762A3 (en) | Detection and treatment of cancers of the colon |